Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Diagnosis of sickle cell disorders

Elliott P Vichinsky, MD
Donald H Mahoney, Jr, MD
Section Editor
Stanley L Schrier, MD
Deputy Editor
Jennifer S Tirnauer, MD


Sickle cell disease (SCD) is an inherited group of disorders characterized by the presence of hemoglobin S (HbS), either from homozygosity for the sickle mutation in the beta globin chain of hemoglobin (HbSS) or from compound heterozygosity of a sickle beta globin mutation with another beta globin mutation (eg, sickle-beta thalassemia). The hallmarks of SCD are vasoocclusive phenomena and hemolytic anemia. Sickle cell trait is a benign carrier condition characterized by heterozygosity for the sickle hemoglobin mutation.

Screening and diagnosis of sickle cell disorders are discussed here.

Discussions of the clinical manifestations and management of sickle cell disorders are presented separately:

(See "Sickle cell trait".)

(See "Overview of variant sickle cell syndromes".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Dec 2016. | This topic last updated: Wed Nov 16 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.
  2. Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.
  3. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254.
  4. Shulman LP, Elias S. Amniocentesis and chorionic villus sampling. West J Med 1993; 159:260.
  5. Lissens W, Sermon K. Preimplantation genetic diagnosis: current status and new developments. Hum Reprod 1997; 12:1756.
  6. Xu K, Shi ZM, Veeck LL, et al. First unaffected pregnancy using preimplantation genetic diagnosis for sickle cell anemia. JAMA 1999; 281:1701.
  7. Lamvu G, Kuller JA. Prenatal diagnosis using fetal cells from the maternal circulation. Obstet Gynecol Surv 1997; 52:433.
  8. Cheung MC, Goldberg JD, Kan YW. Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood. Nat Genet 1996; 14:264.
  9. Vrettou C, Traeger-Synodinos J, Tzetis M, et al. Real-time PCR for single-cell genotyping in sickle cell and thalassemia syndromes as a rapid, accurate, reliable, and widely applicable protocol for preimplantation genetic diagnosis. Hum Mutat 2004; 23:513.
  10. Bermudez MG, Piyamongkol W, Tomaz S, et al. Single-cell sequencing and mini-sequencing for preimplantation genetic diagnosis. Prenat Diagn 2003; 23:669.
  11. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230:1350.
  12. Li HH, Gyllensten UB, Cui XF, et al. Amplification and analysis of DNA sequences in single human sperm and diploid cells. Nature 1988; 335:414.
  13. Embury SH, Scharf SJ, Saiki RK, et al. Rapid prenatal diagnosis of sickle cell anemia by a new method of DNA analysis. N Engl J Med 1987; 316:656.
  14. Chehab FF, Doherty M, Cai SP, et al. Detection of sickle cell anaemia and thalassaemias. Nature 1987; 329:293.
  15. Saiki RK, Bugawan TL, Horn GT, et al. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature 1986; 324:163.
  16. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A 1989; 86:6230.
  17. Chehab FF, Kan YW. Detection of sickle cell anaemia mutation by colour DNA amplification. Lancet 1990; 335:15.
  18. Fischel-Ghodsian N, Hirsch PC, Bohlman MC. Rapid detection of the hemoglobin C mutation by allele-specific polymerase chain reaction. Am J Hum Genet 1990; 47:1023.
  19. Kropp GL, Cornett PA, Leavitt AD, et al. Resolution of complex genotypes containing hemoglobin C genes using the allele-specific fluorescence polymerase chain reaction (abstract). Blood 1990; 76 (Suppl 1):257a.
  20. Gonzalez-Redondo JM, Stoming TA, Lanclos KD, et al. Clinical and genetic heterogeneity in black patients with homozygous beta-thalassemia from the southeastern United States. Blood 1988; 72:1007.
  21. Gonzalez-Redondo JM, Kutlar A, Kutlar F, et al. Molecular characterization of Hb S(C) beta-thalassemia in American blacks. Am J Hematol 1991; 38:9.
  22. Sutcharitchan P, Saiki R, Huisman TH, et al. Reverse dot-blot detection of the African-American beta-thalassemia mutations. Blood 1995; 86:1580.
  23. Almeida AM, Henthorn JS, Davies SC. Neonatal screening for haemoglobinopathies: the results of a 10-year programme in an English Health Region. Br J Haematol 2001; 112:32.
  24. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593.
  25. Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988; 81:749.
  26. Lorey FW, Arnopp J, Cunningham GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol 1996; 13:501.
  27. Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009; 52:486.
  28. Motulsky AG. Frequency of sickling disorders in U.S. blacks. N Engl J Med 1973; 288:31.
  29. Odame I. Developing a global agenda for sickle cell disease: report of an international symposium and workshop in Cotonou, Republic of Benin. Am J Prev Med 2010; 38:S571.
  30. Rahimy MC, Gangbo A, Ahouignan G, Alihonou E. Newborn screening for sickle cell disease in the Republic of Benin. J Clin Pathol 2009; 62:46.
  31. Panepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr 2000; 136:201.
  32. Cronin EK, Normand C, Henthorn JS, et al. Organisation and cost-effectiveness of antenatal haemoglobinopathy screening and follow up in a community-based programme. BJOG 2000; 107:486.
  33. Henthorn JS, Almeida AM, Davies SC. Neonatal screening for sickle cell disorders. Br J Haematol 2004; 124:259.
  34. Consensus conference. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA 1987; 258:1205.
  35. Tsevat J, Wong JB, Pauker SG, Steinberg MH. Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr 1991; 118:546.
  36. Harris MS, Eckman JR. Georgia's experience with newborn screening: 1981 to 1985. Pediatrics 1989; 83:858.
  37. Landenberger G, State of Connecticut newborn experience 1987-1992, 1993, personal communication.
  38. US Preventive Services Task Force. Screening for sickle cell disease in newborns: recommendation statement. Am Fam Physician 2008; 77:1300.
  39. Bain BJ. Neonatal/newborn haemoglobinopathy screening in Europe and Africa. J Clin Pathol 2009; 62:53.
  40. Section on Hematology/Oncology Committee on Genetics, American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics 2002; 109:526.
  41. Strahan JE, Canfield MA, Drummond-Borg LM, Neill SU. Ethnic and gender patterns for the five congenital disorders in Texas from 1992 through 1998. Tex Med 2002; 98:80.
  42. Centers for Disease Control and Prevention (CDC). Update: newborn screening for sickle cell disease--California, Illinois, and New York, 1998. MMWR Morb Mortal Wkly Rep 2000; 49:729.
  43. Hoppe CC. Newborn screening for hemoglobin disorders. Hemoglobin 2011; 35:556.
  44. Kavanagh PL, Wang CJ, Therrell BL, et al. Communication of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states. Am J Med Genet C Semin Med Genet 2008; 148C:15.
  45. Schneider RG. Laboratory identification of hemoglobin variants in the newborn. In: Genetic Disease - Screening and Management, Carter TP, Wiley AM (Eds), Liss, New York 1986. p.137.
  46. National Committee for Clinical Laboratory Standards (NCCLS): Blood collection on filter paper for neonatal screening programs. NCCLS 1988; vol 5, #14 Publication LA4-T.
  47. Reed W, Lane PA, Lorey F, et al. Sickle-cell disease not identified by newborn screening because of prior transfusion. J Pediatr 2000; 136:248.
  48. Jinks DC, Minter M, Tarver DA, et al. Molecular genetic diagnosis of sickle cell disease using dried blood specimens on blotters used for newborn screening. Hum Genet 1989; 81:363.
  49. Rahimy MC, Gangbo A, Ahouignan G, et al. Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting. Blood 2003; 102:834.
  50. Okpala I, Thomas V, Westerdale N, et al. The comprehensiveness care of sickle cell disease. Eur J Haematol 2002; 68:157.
  51. Peters M, Fijnvandraat K, van den Tweel XW, et al. One-third of the new paediatric patients with sickle cell disease in The Netherlands are immigrants and do not benefit from neonatal screening. Arch Dis Child 2010; 95:822.
  52. Bhardwaj U, Zhang YH, Jackson DS, et al. DNA diagnosis confirms hemoglobin deletion in newborn screen follow-up. J Pediatr 2003; 142:346.
  53. McGann PT, Schaefer BA, Paniagua M, et al. Characteristics of a rapid, point-of-care lateral flow immunoassay for the diagnosis of sickle cell disease. Am J Hematol 2016; 91:205.
  54. Quinn CT, Paniagua MC, DiNello RK, et al. A rapid, inexpensive and disposable point-of-care blood test for sickle cell disease using novel, highly specific monoclonal antibodies. Br J Haematol 2016; 175:724.
  55. Kanter J, Telen MJ, Hoppe C, et al. Validation of a novel point of care testing device for sickle cell disease. BMC Med 2015; 13:225.
  56. Piety NZ, Yang X, Kanter J, et al. Validation of a Low-Cost Paper-Based Screening Test for Sickle Cell Anemia. PLoS One 2016; 11:e0144901.
  57. Ryan K, Bain BJ, Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol 2010; 149:35.
  58. Dover GJ, Boyer SH, Charache S, Heintzelman K. Individual variation in the production and survival of F cells in sickle-cell disease. N Engl J Med 1978; 299:1428.
  59. Nagel RL, Ranney HM. Genetic epidemiology of structural mutations of the beta-globin gene. Semin Hematol 1990; 27:342.
  60. Oner C, Dimovski AJ, Altay C, et al. Sequence variations in the 5' hypersensitive site-2 of the locus control region of beta S chromosomes are associated with different levels of fetal globin in hemoglobin S homozygotes. Blood 1992; 79:813.
  61. Diop S, Thiam D, Cisse M, et al. New results in clinical severity of homozygous sickle cell anemia, in Dakar, Senegal. Hematol Cell Ther 1999; 41:217.
  62. West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol 1992; 45:893.
  63. Bunn HF. Subunit assembly of hemoglobin: an important determinant of hematologic phenotype. Blood 1987; 69:1.
  64. Bunn, HF, Forget, BG. Hemoglobin: Molecular, Genetic and Clinical Aspects, WB Saunders, Philadelphia 1986.
  65. Bain BJ. Haemoglobinopathy Diagnosis, 2nd ed, Blackwell, 2006.